Company profile
Immuneering Corporation
NASDAQ: IMRX · Healthcare · Biotechnology
#1161 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
43DFH 61DQ 27GM 19SS 46
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$56.0M
Employees
55
as of 2026-08-14
Market cap
$188.8M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$56.0M-$56.0M2025
Operating income-$59.4M-$59.4M2025
Total assets$232.0M$232.0M2025
Liabilities$13.5M$13.5M2025
Equity$218.5M$218.5M2025
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Immuneering Corporation’s revenue?
Immuneering Corporation booked $0 in FY2023 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Minerva Neurosciences, Inc.37DEupraxia Pharmaceuticals Inc.42DCorbus Pharmaceuticals Holdings, Inc.46DNkarta, Inc.47DOnKure Therapeutics, Inc.46DTuHURA Biosciences, Inc.36DNeighbors
Middlesex →Key facts
CEOBenjamin J. Zeskind
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: IMRX
Employees55
IPO date2021-07-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.